Education
About Us
Working with TipRanks
Follow Us
ESSA Pharma Inc. (EPIX)
:EPIX
EPIX Stock Chart & Stats
$0.20
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial FlexibilityEPIX's last reported cash balance of $126.8M offers flexibility to evaluate opportunities.
Strategic OpportunitiesThe company will move to a strategic process in which it will explore options that maximize shareholder value.
Bears Say
Clinical TrialsEPIX announced the discontinuation of masofaniten's randomized Phase II trial in combination with enzalutamide in anti-androgen naive mCPRC following an interim analysis that suggested the trial was unlikely to meet the primary endpoint.
Drug DevelopmentEPIX announced that it will discontinue all masofaniten development following a pre-specified futility analysis that showed that this candidate failed to meet the target efficacy profile in the Phase 2 enzalutamide combo study in mCRPC patients naïve to second-generation antiandrogens.
ESSA Pharma News
EPIX FAQ
What was ESSA Pharma Inc.’s price range in the past 12 months?
Currently, no data Available
What is ESSA Pharma Inc.’s market cap?
Currently, no data Available
When is ESSA Pharma Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ESSA Pharma Inc.’s earnings last quarter?
ESSA Pharma Inc. released its earnings results on Aug 13, 2025. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.17 by $0.08.
Is ESSA Pharma Inc. overvalued?
According to Wall Street analysts ESSA Pharma Inc.’s price is currently Undervalued.
Does ESSA Pharma Inc. pay dividends?
ESSA Pharma Inc. does not currently pay dividends.
What is ESSA Pharma Inc.’s EPS estimate?
ESSA Pharma Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ESSA Pharma Inc. have?
Currently, no data Available
What happened to ESSA Pharma Inc.’s price movement after its last earnings report?
ESSA Pharma Inc. reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.17. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of ESSA Pharma Inc.?
Currently, no hedge funds are holding shares in EPIX
Company Description
ESSA Pharma Inc.
ESSA Pharma Inc. (EPIX) is a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer. The company operates within the biotechnology and pharmaceutical sectors, with its core products centering around small molecule drugs that target the androgen receptor pathway in prostate cancer cells. ESSA Pharma's lead product candidate is EPI-7386, a next-generation androgen receptor inhibitor designed to provide therapeutic benefits for patients with metastatic castration-resistant prostate cancer (mCRPC).